fbpx Skip to main content

Member's Profile

PrimeVax Immuno-Oncology, Inc.

2229 West Mills Drive
Orange,   CA
United States
Membership Info
Membership Type: Industry
Membership Since: 2019
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About PrimeVax Immuno-Oncology, Inc.
Biotech Company
PrimeVax Immuno-Oncology, Inc. is focused on the development of personalized immunotherapy with its PV-001 platform. The platform’s goal is to enable a 1-time 1-week cancer treatment schedule for many cancer types. PV-001 leverages the body’s innate and adaptive immune responses simultaneously to trigger activation of T cells, NK cells, and other immunotherapeutic effects. The Company was founded in 2015 and will engage in human clinical trials in 2019. Initial indications to be targeted include metastatic melanoma, triple negative breast cancer, and glioblastoma.
Related News
No related news posted by this Member